Croda Strengthens Board with Appointment of Healthcare Veteran Jill Anderson

An update from Croda International ( (GB:CRDA) ) is now available.

Croda International has appointed Jill Anderson as a Non-Executive Director, effective 12 January 2026, and she will also serve on the Audit, Nomination and Remuneration Committees. Anderson brings over three decades of international leadership experience in the healthcare industry, including her recent role as Chief Financial Officer of GSK’s R&D division and her current position as a Non-Executive Director and Audit Committee Chair at Spire Healthcare, strengthening Croda’s board with deep financial and sector expertise that is expected to support the company’s strategic ambitions in innovation-led, health-focused markets.

The most recent analyst rating on (GB:CRDA) stock is a Hold with a £2914.00 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.

Spark’s Take on GB:CRDA Stock

According to Spark, TipRanks’ AI Analyst, GB:CRDA is a Neutral.

Croda International’s overall stock score reflects a mix of solid financial health and strategic initiatives, tempered by valuation concerns and technical weaknesses. The company’s strong earnings call and positive corporate events provide a supportive backdrop, but investors should be cautious of the high P/E ratio and bearish technical indicators.

To see Spark’s full report on GB:CRDA stock, click here.

More about Croda International

Croda International Plc is a UK-based specialty chemicals company that focuses on using innovation and “smart science” to develop ingredients and solutions designed to improve lives, with a notable presence in healthcare-related applications and other performance-driven markets.

Average Trading Volume: 654,846

Technical Sentiment Signal: Strong Sell

Current Market Cap: £3.85B

For an in-depth examination of CRDA stock, go to TipRanks’ Overview page.